Vol. 5 No. 12 (2025)
Reimbursement Reviews

Pembrolizumab (Keytruda)

decorative image of the issue cover

Published December 19, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Pembrolizumab (Keytruda), 100 mg/4 mL vial, solution for infusion, IV infusion.
  • Indication: In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma.